Predictors and outcomes associated with hydroxyurea sensitivity in acute myeloid leukemia patients with high hyperleukocytosis
暂无分享,去创建一个
H. Dombret | M. Sébert | L. Adès | É. Azoulay | R. Itzykson | N. Boissel | E. Raffoux | V. Lemiale | E. Lengliné | M. Cerrano | V. Seegers | F. Rabian
[1] R. Itzykson,et al. New Treatment Options for Acute Myeloid Leukemia in 2019 , 2019, Current Oncology Reports.
[2] Torsten Haferlach,et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. , 2018, Blood.
[3] M. Carroll,et al. Dexamethasone in hyperleukocytic acute myeloid leukemia , 2018, Haematologica.
[4] P. Qiu,et al. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy , 2016, American journal of hematology.
[5] H. Dombret,et al. Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia , 2016, Leukemia & lymphoma.
[6] G. Ehninger,et al. How I treat hyperleukocytosis in acute myeloid leukemia. , 2015, Blood.
[7] J. Beyene,et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis. , 2014, Leukemia research.
[8] M. Tallman,et al. How I treat hematologic emergencies in adults with acute leukemia. , 2012, Blood.
[9] R. Hills,et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.
[10] Bob Löwenberg,et al. Review Articles (434 articles) , 2008 .
[11] F. Mannelli,et al. Peripheral blood blast clearance during induction therapy in acute myeloid leukemia. , 2008, Blood.
[12] A. Schechter,et al. Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. , 2006, Blood.
[13] J. Harbott,et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995 , 2000, Leukemia.
[14] R. E. Cunningham,et al. Schedule-dependent synergism of combinations of hydroxyurea with adriamycin and 1-beta-D-arabinofuranosylcytosine with adriamycin. , 1981, Cancer research.
[15] S. Chevret,et al. Inclusion of patients with acute leukemia in clinical trials: a prospective multicenter survey of 1066 cases. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.